[go: up one dir, main page]

WO2004045718A3 - Treatment of cognitive dysfunctions' - Google Patents

Treatment of cognitive dysfunctions' Download PDF

Info

Publication number
WO2004045718A3
WO2004045718A3 PCT/US2003/036813 US0336813W WO2004045718A3 WO 2004045718 A3 WO2004045718 A3 WO 2004045718A3 US 0336813 W US0336813 W US 0336813W WO 2004045718 A3 WO2004045718 A3 WO 2004045718A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
day
treatment
reuptake
cognitive dysfunctions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/036813
Other languages
French (fr)
Other versions
WO2004045718A2 (en
Inventor
Srinivas G Rao
Jay D Kranzler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cypress Bioscience Inc
Original Assignee
Cypress Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cypress Bioscience Inc filed Critical Cypress Bioscience Inc
Priority to AU2003298664A priority Critical patent/AU2003298664A1/en
Publication of WO2004045718A2 publication Critical patent/WO2004045718A2/en
Publication of WO2004045718A3 publication Critical patent/WO2004045718A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Cognitive dysfunction can be treated by administering to a mammal an effective amount of a compound that is an N-methyl-D-aspartate (NMDA) receptor antagonist and a selective norepinephrine (NE) serotonin (5-HT) reuptake inhibitor (NSRI), most preferably between 1:1 and 20:1 NE:5-HT reuptake. In a preferred embodiment the composition includes a pharmaceutically acceptable carrier and an effective cognition-enhancing amount of milnacipran, most preferably about 25 mg/day to about 250 mg/day. The composition may further include at least one of Ginkgo biloba, Huperzine A, Phosphatidylserine, Vitamin E, Tacrine, Donepezil, Rivastigmine, and Galantamine. The composition can also include at least one of sibutramine, an aminocyclopropane derivative, venlafaxine, duloxetine, desipramine, nortriptyline, protriptyline, amitriptyline, clomipramine, doxepine, imipramine, and trimipramine.
PCT/US2003/036813 2002-11-20 2003-11-18 Treatment of cognitive dysfunctions' Ceased WO2004045718A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003298664A AU2003298664A1 (en) 2002-11-20 2003-11-18 Treatment of cognitive dysfunctions'

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US42776702P 2002-11-20 2002-11-20
US60/427,767 2002-11-20
US44314203P 2003-01-28 2003-01-28
US60/443,142 2003-01-28
US47976103P 2003-06-18 2003-06-18
US60/479,761 2003-06-18

Publications (2)

Publication Number Publication Date
WO2004045718A2 WO2004045718A2 (en) 2004-06-03
WO2004045718A3 true WO2004045718A3 (en) 2004-08-12

Family

ID=32329863

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/036813 Ceased WO2004045718A2 (en) 2002-11-20 2003-11-18 Treatment of cognitive dysfunctions'

Country Status (2)

Country Link
AU (1) AU2003298664A1 (en)
WO (1) WO2004045718A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US20030232805A1 (en) * 2002-04-24 2003-12-18 Cypress Bioscience, Inc. Prevention and treatment of functional somatic disorders, including stress-related disorders
AR043467A1 (en) * 2003-03-05 2005-07-27 Osmotica Argentina S A DRUG COMBINATION FOR MOTOR DYSFUNCTION IN PARKINSON'S DISEASE
GB0309440D0 (en) * 2003-04-25 2003-06-04 Lilly Co Eli Quinolone derivatives
TW200800959A (en) 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
US20080058318A1 (en) * 2006-08-09 2008-03-06 Cypress Bioscience, Inc. Milnacipran for the treatment of cognitive dysfunction associated with fibromyalgia
GB0701970D0 (en) 2007-02-01 2007-03-14 Wilson Stuart Treatment of protein aggregation diseases
FR2978350B1 (en) 2011-07-28 2013-11-08 Pf Medicament LEVOMILNACIPRAN-BASED MEDICINAL PRODUCT FOR FUNCTIONAL REHABILITATION AFTER ACUTE NEUROLOGICAL ACCIDENT
WO2013166468A1 (en) * 2012-05-04 2013-11-07 Insero Health Inc. Compositions and methods for treating neurodegenerative diseases
US11957692B2 (en) 2022-05-23 2024-04-16 National Institute Of Immunology Clomipramine for the treatment of Alzheimer's Disease

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] MONTGOMERY ET AL: "Efficacy and tolerability of milnacipran: An overview", XP002978327, Database accession no. (PREV199799295265) *
DATABASE IMSPRODUCT [online] "N7D anti-alzheimer products", Database accession no. 2002:12875 *
DRUG LAUNCHES, 28 October 2002 (2002-10-28), pages 1 - 27 *
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, vol. 11, no. 4, 1996, pages 47 - 51 *

Also Published As

Publication number Publication date
AU2003298664A1 (en) 2004-06-15
WO2004045718A2 (en) 2004-06-03
AU2003298664A8 (en) 2004-06-15

Similar Documents

Publication Publication Date Title
WO2004045718A3 (en) Treatment of cognitive dysfunctions'
MXPA02001820A (en) Composition comprising a tramadol material and an anticonvulsant drug.
JP2020019818A (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for treating agitation in dementia
HUP0201623A3 (en) Use of (s,s)reboxetine a selective norepinephrine reuptake inhibitor for the preparation of pharmaceutical compositions treating disorders of the nervous system
US20100280129A1 (en) Method of Treating Pain Caused by Inflammation
TNSN98176A1 (en) TOPICAL PHARMACEUTICAL COMPOSITIONS CONTAINING RESORCINOL DERIVATIVES
WO2006010544A3 (en) 1, 1a, 5, 5a-tetrahydro-3-thia-cyclopropa’a! pentalenes: tricyclic thiophene derivatives as s1p1/edg1 receptor agonists
CN101050199A (en) (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
US6172105B1 (en) Composition and methods employing it for the treatment of 5-HT-mediated disorders
CA2353133A1 (en) Treatment of disorders secondary to organic impairments
CA2386793A1 (en) New selective retinoid agonists
SG172712A1 (en) Treating psychological conditions using muscarinic receptor m1 antagonists
WO2000002551A3 (en) Methods and compounds for treating depression
CN100430063C (en) Combinations using 5-hydroxytryptamine reuptake inhibitors
WO2003018515A3 (en) Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
EP1509220A4 (en) A pharmaceutical composition for the treatment of seborrhea containing 4-hydroxy-5-methoxy-4- 2-methyl-3(3-methyl-2-butenyl)-2-oxiranyl -1-oxaspiro 2,5 octan-6-one
JP2575569B2 (en) Use of glycine / NMDA receptor ligand for the treatment of drug dependence and withdrawal symptoms
Cooper Future synthetic drugs of abuse
Panerai et al. Antidepressants in cancer pain
Van Den Berg Comparing SSRIs: from chemistry to clinical choice
TR199800164T1 (en) Preparation of norbenzomorphan useful in pharmacology.
WO2007056454A3 (en) Use of cicletanine and other furopyridines for treatment of hypertension
US20170065560A1 (en) Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indo]-4-amine and Antidepressants
EP0768083A3 (en) The use of sertraline to treat post myocardial infarction patients
CA2346335A1 (en) Sertraline oral concentrate

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP